Ultrafast, Single B Cell-based Anti-idiotypic mAb Discovery Against a mAb Therapeutic

Products

Applications

Resources

COMPANY

Ultrafast, Single B Cell-based Anti-idiotypic mAb Discovery Against a mAb Therapeutic

Download the Case Study

Case study showcasing Delivery of PK assay-ready mAbs in 11 weeks to meet aggressive clinical timelines.

Covered in this Case Study

11 weeks from the start of immunization to delivery of validated small-scale purified antibodies with sequences

High-quality mAbs delivered–specific, high-affinity mAbs with blocking and non-blocking profiles

Partner was able to develop highly sensitive PK assay and move clinical trials forward on time

Share your details to Get the Case Study